Teriparatide biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Drug Profile

Teriparatide biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Alternative Names: Recombinant human parathyroid hormone 1-34 - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical; rhPTH1-34 - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Osteoporosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Osteoporosis in China (SC)
  • 14 May 2015 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans to submit a phase II application for Osteoporosis to Chinese SFDA in second half of 2015
  • 24 Mar 2015 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase I trial in Osteoporosis in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top